Effectiveness of concomitant setiptiline maleate (Tecipul) on negative symptoms of schizophrenia.
1. Setiptiline maleate was administered to schizophrenic patients with the object of improving their negative symptoms. 2. Moderate improvements were observed in 58% of the treated patients, thus usefulness of this drug was demonstrated. 3. There was no aggravation of symptoms, and side effects were minor. 4. Measurements of plasma monoamine metabolites showed a tendency of MHPG to decrease and a significant decrease in 5-HIAA, but no change in the level of HVA was observed, suggesting a relationship between the negative symptoms and noradrenaline and/or serotonin systems.
Kuniyoshi
M
M
Chikusuikai Hospital, Chikusuikai Institute for Neuroinformation, Yame-city, Japan.
Nakamura
J
J
Miura
C
C
Inanaga
K
K
D000328:Adult; D015306:Biogenic Monoamines / Q000097:blood; D002908:Chronic Disease; D005260:Female; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000097:blood; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000097:blood / Q000188:drug therapy*; D012565:Schizophrenic Psychology; D012702:Serotonin Antagonists / Q000009:adverse effects / Q000627:therapeutic use*
D015306:Biogenic Monoamines; D012702:Serotonin Antagonists; D008803:Mianserin; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; C050605:setiptiline; D006719:Homovanillic Acid